IDH1 and glioblastoma: As the original aim of this study was to assess the differences in PKM2 expression between GBM (IDH wild type) and ASTROG4 (IDH R132H mutant), our findings suggest that PKM2 expression, particularly the intensity score, could serve as a prognostic marker of disease severity across both groups.